Literature DB >> 24159423

Absence of Nitric Oxide Synthase 3 Increases Amyloid β-Protein Pathology in Tg-5xFAD Mice.

Zishuo Ian Hu1, Ann Marie E Kotarba, William E Van Nostrand.   

Abstract

AIM: The abnormal accumulation, assembly and deposition of the amyloid β-protein (Aβ) are prominent pathological features of patients with Alzheimer's disease (AD) and related disorders. A number of factors in the brain can influence Aβ accumulation and associated pathologies. The aim of the present study was to determine the consequences of deleting nitric oxide synthase (NOS) 3, the endothelial form of NOS, in Tg-5xFAD mice, a model of parenchymal AD-like amyloid pathology.
METHODS: Tg-5xFAD mice were bred with NOS3-/- mice. Cohorts of Tg-5xFAD mice and bigenic Tg-5xFAD/NOS3-/- mice were aged to six months followed by collection of the blood and brain tissues from the mice for biochemical and pathological analyses.
RESULTS: ELISA analyses show that the absence of NOS3 results in elevated levels of cerebral and plasma Aβ peptides in Tg-5xFAD mice. Immunohistochemical analyses show that the absence of NOS3 increased the amount of parenchymal Aβ deposition and fibrillar amyloid accumulation in Tg-5xFAD mice. The elevated levels of Aβ were not due to changes in the expression levels of transgene encoded human amyloid precursor protein (APP), endogenous β-secretase, or increased proteolytic processing of APP.
CONCLUSIONS: The results from this study suggest that the loss of NOS3 activity enhances Aβ pathology in Tg-5xFAD mice. These findings are similar to previous studies of NOS2 deletion suggesting that reduced NOS activity and NO levels enhance amyloid-associated pathologies in human APP transgenic mice.

Entities:  

Keywords:  Alzheimer’s Disease; Amyloid β-Protein; Deposition; Nitric Oxide Synthase 3; Transgenic Mice

Year:  2013        PMID: 24159423      PMCID: PMC3804905          DOI: 10.4236/nm.2013.42013

Source DB:  PubMed          Journal:  Neurosci Med        ISSN: 2158-2912


  38 in total

1.  Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease.

Authors:  K Johnson-Wood; M Lee; R Motter; K Hu; G Gordon; R Barbour; K Khan; M Gordon; H Tan; D Games; I Lieberburg; D Schenk; P Seubert; L McConlogue
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

2.  Declining expression of neprilysin in Alzheimer disease vasculature: possible involvement in cerebral amyloid angiopathy.

Authors:  Mélanie Carpentier; Yves Robitaille; Luc DesGroseillers; Guy Boileau; Mieczyslaw Marcinkiewicz
Journal:  J Neuropathol Exp Neurol       Date:  2002-10       Impact factor: 3.685

3.  Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains.

Authors:  A Pérez; L Morelli; J C Cresto; E M Castaño
Journal:  Neurochem Res       Date:  2000-02       Impact factor: 3.996

4.  Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40).

Authors:  J R Backstrom; G P Lim; M J Cullen; Z A Tökés
Journal:  J Neurosci       Date:  1996-12-15       Impact factor: 6.167

5.  Elevated blood pressures in mice lacking endothelial nitric oxide synthase.

Authors:  E G Shesely; N Maeda; H S Kim; K M Desai; J H Krege; V E Laubach; P A Sherman; W C Sessa; O Smithies
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

Review 6.  Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.

Authors:  R Deane; R D Bell; A Sagare; B V Zlokovic
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-03       Impact factor: 4.388

Review 7.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

Review 8.  Pathogenesis of cerebral amyloid angiopathy.

Authors:  Annemieke A M Rensink; Robert M W de Waal; Berry Kremer; Marcel M Verbeek
Journal:  Brain Res Brain Res Rev       Date:  2003-10

9.  Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus.

Authors:  R E Tanzi; J F Gusella; P C Watkins; G A Bruns; P St George-Hyslop; M L Van Keuren; D Patterson; S Pagan; D M Kurnit; R L Neve
Journal:  Science       Date:  1987-02-20       Impact factor: 47.728

10.  Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2.

Authors:  Donna M Wilcock; Matthew R Lewis; William E Van Nostrand; Judianne Davis; Mary Lou Previti; Nastaran Gharkholonarehe; Michael P Vitek; Carol A Colton
Journal:  J Neurosci       Date:  2008-02-13       Impact factor: 6.167

View more
  3 in total

Review 1.  Blood-brain barrier leakage in Alzheimer's disease: From discovery to clinical relevance.

Authors:  Geetika Nehra; Bjoern Bauer; Anika M S Hartz
Journal:  Pharmacol Ther       Date:  2022-01-30       Impact factor: 13.400

2.  Proinflammatory cytokines induce accumulation of glypican-1-derived heparan sulfate and the C-terminal fragment of β-cleaved APP in autophagosomes of dividing neuronal cells.

Authors:  Fang Cheng; Lars-Åke Fransson; Katrin Mani
Journal:  Glycobiology       Date:  2020-07-16       Impact factor: 4.313

3.  Mouse models of Alzheimer's disease cause rarefaction of pial collaterals and increased severity of ischemic stroke.

Authors:  Hua Zhang; Bo Jin; James E Faber
Journal:  Angiogenesis       Date:  2018-12-05       Impact factor: 9.596

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.